Tolododekin alfa is an anchored interleukin-12 conjugate enhancing tumour retention. Here, this group reports a Phase 1 trial evaluating the safety and biological activity of tolododekin alfa in patients with different advanced solid tumours.
- Jong Chul Park
- Brendan Curti
- John M. Kirkwood